State of the art: Standard(s) of radio/chemotherapy for rectal cancer
|
|
|
- Oswald Fowler
- 5 years ago
- Views:
Transcription
1 State of the art: Standard(s) of radio/chemotherapy for rectal cancer Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey
2 Disclosure Advisory Board: Sanofi Oncology, Eli- Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, Five Prime Therapeutics Research funding: Eli-Lilly, Janssen-Cilag, Sanofi Oncology, Merck-Serono, Novartis Honorarium: Taiho, Pfizer, Amgen, Eli- Lilly
3 Why are we NOT improving Superior local control with surgery alone survival with CRT? Reducing distant metastases Clinical benefit Sensitivity and resistance to (C)RT Improving efficacy over CRT
4 Why are we NOT improving survival with CRT? Clinical benefit
5 T3 (<5mm) N+ve rectal tumours
6 Good prognosis rectal cancer managed by surgery alone (no RT) - MERCURY Disease free survival Overall survival T3 <5mm extramural spread, regardless of N stage Local recurrence 1.7% 5-year DFS: 81% 5-year OS: 67.9% Taylor et al Ann Surg 2011
7 Why are we NOT improving survival with CRT? Superior local control with surgery alone Reducing distant metastases Clinical benefit Improving efficacy over CRT
8 Pre-operative CRT: ct3-4 or N+ Study n Local recurrence 5-year DFS 5-year OS German CAO/ARO/AIO-94 1 Pre-op CRT 421 5% 68% 74% Post-op CRT % 65% 76% p=0.048 p=0.32 p=0.80 FFCD Pre-op CRT % 59.4% 67.4% Pre-op RT % 55.5% 67.9% p=0.004 p=0.684 EORTC Pre-op CRT % 56.1% 65.8% Pre-op RT % 54.4% 64.8% p=0.002 p=0.52 p= Sauer et al J Clin Oncol 2012; 2 Gerard J et al J Clin Oncol 2006; 3 Bosset et al N Engl J Med 2006
9 Efficacy of adding oxaliplatin to FP/RT in rectal cancer Trials Arms n pcr p DFS OS STAR-01 1 FU % NR NR OX/FU % ACCORD 12/ CAP % % 87.6% 0405 PRODIGE 2 2 CAPOX % 72.7% 88.3% HR: 0.88 HR: 0.94 German Rectal 3 FU % % 88.0% CAO/ARO/AIO-04 OX/FU % 75.9% 88.7% HR: 0.79 HR: 0.96 NSABP R-04 4,5 FP % % * 79% * OX/FP % 69.2% * 81.3% * p=0.34 p=0.38 PETACC-6 CAP % NR 74.5% 89.5% CAPOX % 73.9% 87.4% * 5-year survival rates p=0.78 p=ns 1 Aschele et al J Clin Oncol 2011; 2 Gerard et al J Clin Oncol 2012; 3 Rodel et al Lancet Oncol 2015; 4 O Connell et al J Clin Oncol 2014; 5 Allegra et al J Natl Cancer Inst 2015; 6 Schmoll et al ASCO 2014
10 Pre-operative CRT: randomised trials Study n Distant metastasis 5-year DFS 5-year OS German CAO/ARO/AIO-94 1 Pre-op CRT % 68% 74% Post-op CRT % 65% 76% p=0.32 p=0.80 FFCD Pre-op CRT % 59.4% 67.4% Pre-op RT % 55.5% 67.9% p=0.684 EORTC Pre-op CRT % 56.1% 65.8% Pre-op RT % 64.8% p=0.52 p= Sauer et al J Clin Oncol 2012; 2 Gerard J et al J Clin Oncol 2006; 3 Bosset et al N Engl J Med 2006
11 Pooled analysis of 5 European RCTs (n=2,795) 5-year 10-year Local recurrence 12.9% 14.3% Distant metastasis 30.8% 34.2% Overall Survival 69.6% 57.3% Valentini et al J Clin Oncol 2011
12 Selecting patients for the right treatment CRYSTAL: FOLFIRI ± cetuximab K-RAS exon 2 mutants K-RAS exons 2-4 N-RAS exons 2-4 mutants All comers mcrc K-RAS wild type RAS wild type HR: 0.796; p= Van Cutsem et al J Clin Oncol 2011, 2015
13 Are all T3 rectal cancers born equal? Circumferential resection margin (CRM) Extramural spread (<5mm vs. >5mm) T4 tumours N0 vs. N1.vs N2 Extramural venous invasion Low lying tumours
14 Meta-analysis of studies comparing CRM +ve vs. ve: Nagtegaal et al J Clin Oncol 2008
15 Extramural spread ( 5mm vs. >5mm) T3a 5-yr LR 5-yr OS T3a 5mm 10.4% 85.4% T3b >5mm 26.3% 54.1% Both p< T3b Merkel et al Int J Colorectal Dis 2001
16 N0 vs. N1 vs. N2 TN staging Pooled analysis 1 1 Pooled analysis 2 2 SEER analysis 3 (total n = 2,551) (total n = 3,791) (total n = 35,829) n 5-yr OS n 5-yr OS n 5-yr OS T3N % 1,060 75% 10,615 64% T3N % % 5, % T3N % % 3, % 1 Gunderson et al Int J Radiat Oncol Biol Phys Gunderson et al J Clin Oncol Gunderson et al J Clin Oncol 2010
17 Extramural venous invasion (EMVI): disease free survival n=478 EMVI was an independent poor prognostic factor on multivariate analyses for stage II rectal cancer HR 2.08 (95% CI ) Stage III rectal cancer HR 2.74 (95% CI ) Chand et al Ann Oncol 2014
18 Low lying tumours: pooled analysis from 5 (chemo)radiotherapy rectal cancer RCTs Local recurrence Overall survival Cancer specific survival APR LAR N 1,353 2,310 CRM +ve 10.6% 5% 5-year LR 19.7% 11.4% 5-yr OS 59.5% 70.1% 5-yr CSS 65.1% 76.6% All p<0.001 den Dulk et al Eur J Cancer 2009
19 Are all rectal cancers born equal? Circumferential resection margin (CRM) Extramural spread (<5mm vs. >5mm) T4 tumours N0 vs. N1.vs N2 Extramural venous invasion Low lying tumours Do we have the right tool to detect these high risk features?
20 Baseline MRI Extramural spread threatening anterior circumferential resection margin Right pelvic side wall node Left pelvic side wall node
21 Baseline MRI Extramural venous invasion
22 MERCURY Circumferential resection margin assessment 1 Number Percentage 95% CI Histological CRM ve 354/408 87% 83-90% MRI predicted CRM-ve 327/354 92% 90-95% MRI prediction CRM-ve 349/408 86% 82-89% Histological CRM-ve 27/349 94% 91-96% MRI Histopathology Mean difference Extramural tumour spread assessment 2 Mean extramural tumour spread 2.80mm (SD 4.60mm) 2.81mm (SD 4.28mm) -0.05mm (95%CI: -0.49mm to 0.40mm) 1 MERCURY Study Group BMJ MERCURY Study Group Radiology 2007
23 Why are we NOT improving survival with CRT? Superior local control with surgery alone Reducing distant metastases Clinical benefit Improving efficacy over CRT
24 Clinico-pathological poor risk factors Circumferential resection margin involvement (CRM) Extramural spread (<5mm vs. >5mm) T4 tumours N0 vs. N1.vs N2 Extramural venous invasion Low lying tumours
25 Serial RMH phase II studies of neoadjuvant chemotherapy, chemoradiation followed by TME Study No. of patients Recruitment period Chemorad 1 36 Jan 99 to Aug 01 EXPERT 2,3 105 Nov 01 to Aug 05 EXPERT-C Aug 05 to Jul 08 1 Chau et al Brit J Cancer 2003; 2 Chau et al J Clin Oncol Chua et al Lancet Oncol 2010; 4 Dewsbury et al J Clin Oncol 2012
26 Trial schema 0 Weeks Neoadjuvant chemotherapy MRI and CT scans at 12 weeks and after radiotherapy to reassess tumour response Chemoradiation Post-operative chemotherapy weeks 4-6 weeks rest for recovery of acute RT toxicity. Repeat MRI then TME SURGERY
27 EXPERT trial schema OXALIPLATIN 130 mg/m 2 0 Weeks CAPECITABINE 2000mg/m 2 /day for 14 days every 21 days MRI and CT scans at 12 weeks and after radiotherapy to reassess tumour response RT 45Gy in 25# phase 1 9Gy boost phase 2 Capecitabine 1650mg/m 2 /day continuously Post operatively CAPECITABINE 2500mg/m 2 /day for 14 days every 21 days weeks 4-6 weeks rest for recovery of acute RT toxicity. Repeat MRI then TME SURGERY Chau et al J Clin Oncol 2006, Chua et al Lancet Oncol 2010
28 Probability of survival / PFS (%) 100 EXPERT: Progression free and overall survival (ITT n=105) Median FU: 55 months 3-year 5-year OS 83% 75% PFS 68% 64% OS PFS Years from trial entry Chua et al Lancet Oncol 2010
29 n=165 R EXPERT-C trial design EXPERT Neoadjuvant oxaliplatin/capecitabine Capecitabine chemoradiation Total mesorectal excision Adjuvant oxaliplatin/capecitabine EXPERT-C Neoadjuvant oxaliplatin/capecitabine/cetuximab Capecitabine/cetuximab chemoradiation Total mesorectal excision Adjuvant oxaliplatin/capecitabine/cetuximab Investigator s sites in UK, Spain and Sweden Recruitment finished in July 2008 Dewdney et al J Clin Oncol 2012
30 After neoadjuvant chemotherapy plus cetuximab After neoadjuvant chemotherapy Baseline
31 After neoadjuvant chemotherapy plus cetuximab Baseline After neoadjuvant chemotherapy
32 After neoadjuvant chemotherapy plus cetuximab Baseline After neoadjuvant chemotherapy
33 After chemoradiation Pathological complete response was achieved on surgical specimen from TME
34 EXPERT-C trial: 5-year results 100 Median follow-up = 64 months % PFS HR 0.62 ( ) p=0.23 CAPOX CAPOX-C % OS HR 0.56 ( ) p=0.20 CAPOX CAPOX-C Time from randomisation (years) 5-year PFS CAPOX 67.8% vs. CAPOX+C 75.4% Time from randomisation (years) 5-year OS CAPOX 72.3% vs. CAPOX+C 84.3% Sclafani et al J Nat Cancer Inst 2014
35 Why are we NOT improving survival with CRT? Superior local control with surgery alone Reducing distant metastases Clinical benefit Improving efficacy over CRT
36 Balancing survival with quality of life Short term toxicities Long term complications Permanent sequelae Local recurrence Distant Cure metastases Clinical benefit
37 What constitutes a good response after CRT? Pathological complete response 1 Pathological Tumour regression grade 2 pcr seen in 16% Significant more T1/2 achieved pcr Do T1/2 tumours need pcr to have better survival? 1 Maas et al Lancet Oncol 2010; 2 Fokas et al J Clin Oncol 2014
38 Efficacy of adding oxaliplatin to FP/RT in rectal cancer Trials Arms n pcr p DFS OS STAR-01 1 FU % NR NR OX/FU % ACCORD 12/ CAP % % 87.6% 0405 PRODIGE 2 2 CAPOX % 72.7% 88.3% HR: 0.88 HR: 0.94 German Rectal 3 FU % % 88.0% CAO/ARO/AIO-04 OX/FU % 75.9% 88.7% HR: 0.79 HR: 0.96 NSABP R-04 4,5 FP % % * 79% * OX/FP % 69.2% * 81.3% * p=0.34 p=0.38 PETACC-6 CAP % NR 74.5% 89.5% CAPOX % 73.9% 87.4% * 5-year survival rates p=0.78 p=ns 1 Aschele et al J Clin Oncol 2011; 2 Gerard et al J Clin Oncol 2012; 3 Rodel et al Lancet Oncol 2015; 4 O Connell et al J Clin Oncol 2014; 5 Allegra et al J Natl Cancer Inst 2015; 6 Schmoll et al ASCO 2014
39 Disease free survival good vs. poor responders: Pathology and MRI ypt0-2 ypt3-4 79% 63% ymrt0-t2 ymrt3-t4 80% 67% Despite a lack of 100% agreement between pathology and MRI, assessment of T stage by either MRI or pathology show equal performance in the prediction of survival Yu et al. Int J Radiat Oncol Biol Phys 2013
40 mrtrg vs. ptrg Sclafani et al Br J Cancer 2017
41 MERCURY: MRI post-crt TRG Based on similar principles to Dworak s pathologic TRG mrtrg 5: no fibrosis evident; tumour signal visible only mrtrg 4: predominantly tumour signal intensity with minimal fibrotic lowsignal intensity mrtrg 3: mixed areas of low-signal fibrosis and intermediate signal intensity present but without predominance of tumour signal mrtrg 2: in-between mrtrg1 and 3 mrtrg 1: absence of any tumour signal Unfavourable: TRG 4-5 Favourable: TRG 1-3 Patel et al J Clin Oncol 2011
42 Correlation between mrtrg and ptrg Sclafani et al Br J Cancer 2017
43 Combining ptrg and mrtrg to predict survival Sclafani et al Br J Cancer 2017
44 TRIGGER: mrtrg as biomarker for stratified management of rectal cancer patients ClinicalTrials.gov NCT
45 Responding to response challenging the paradigm What is the optimal time for surgery? To wait (a long time) seems better
46 Low-lying rectal cancer
47 Watch & Wait/ Deferral of Surgery with post CRT complete clinical response Initially triumphed by Habr-Gama et al A number of retrospective institutional series and registry data supported this approach Actuarial local regrowth rates in patients with clinical complete response to CRT managed by watch & wait 1 34% had tumour local regrowth Of whom 88% had salvage therapy with surgery (76%) and contact RT (12%) Renehan et al Lancet Oncol 2016
48 Royal Marsden Deferral of Surgery Prospective Study MRI defined complete response: mrtrg1-2: low signal intensity fibrotic scar tissue only seen at MRI performed 4 weeks after long-course CRT, confirmed at 8-12 week MRI Clinical follow-up MRI PET Sigmoidoscopy CT & colonoscopy 1M, 2M, 3Mly 1-2 yrs, 6Mly 3-4 yrs, then annually 1M, 2M, 3Mly 1 st yr, 6Mly 2 nd yr, annually 2M, 4M, 1 yr 3Mly Yr 1, 6Mly Yr 2, annually As per current NICE guidelines Primary endpoint: Local Failure Powered for unacceptable failure rate 80% power <15% local recurrence at 2 years Safe deferral 90% power 10% defer expected to be at least 25% Success 11 of 59 patients safely defer surgery at 2 years NCT
49 Responding to response challenging the paradigm What is the optimal time for surgery? To wait (longer) seems better
50 Timing after CRT? When is maximum response reached? Baseline mrt4 invading Bladder and peritoneum 6 weeks ymrt3b After completing CRT, patients undergoing surgery with a delay 8 weeks are 3x more likely to undergo T downstaging than patients <8 weeks (OR, 3.79; CI: ; P<0.03). pcr: 17.8% in delayed group; 5.5% in standard group 12 weeks ymrt2 Final Pathology: ypt2n0 Evans et al Dis Colon Rectum 2011
51 RCT Optimal timing for surgery after preoperative CRT (6 vs. 12 weeks) MRI-defined poor risk rectal cancer: CRM <1mm Low-lying tumour T3 (>5mm extramural spread) EMVI +ve N2 R n=122 n=115 Surgery 6 weeks post CRT Surgery 12 weeks post CRT Primary endpoint: Tumour downstaging rates as defined as the proportion of patients downstaged by T staging seen on post CRT MRI To detect in mrt downstaging from an expected 40% in the 6 weeks arm to 60% in the 12 weeks arm, 218 patients would be required (80% power; 2-sided =0.0492) Evans et al ESCP, ESMO 2016
52 RCT Optimal timing for surgery after preoperative CRT (6 vs. 12 weeks) Recruited from 22 centres from UK, Brazil, Canada and Cyprus between Oct 09 and Dec 14 6 weeks 12 weeks N Primary endpoint: mrt-downstaging 52 (43%) 67 (58%) Relative Risk: 1.4; 95% CI: 1.1, 1.8; p=0.019 Evans et al ESCP, ESMO 2016
53 RCT Optimal timing for surgery after preoperative CRT (6 vs. 12 weeks) 6 weeks 12 weeks mrtrg 1 7 (6%) 21 (22%) 2 31 (28%) 29 (30%) 3 45 (41%) 81 (39%) 4 22 (20%) 31 (15%) 5 6 (5%) 8 (4%) Differences in mrtrg between the two arms were significant (p=0.0006) Evans et al ESCP, ESMO 2016
54 RCT Optimal timing for surgery after pre-operative CRT (6 vs. 12 weeks) Pathological findings 6 weeks 12 weeks N ypcr 11 (11%) 23 (24%) ypt0 9 (9%) 23 (24%) ypn0 48 (50%) 62 (65%) ypcrm +ve 8 (8%) 11 (11%) Specimen grade 1 complete 68 (71%) 65 (68%) 2 near complete 14 (15%) 13 (14%) 3 incomplete 4 (4%) 10 (10%) Evans et al ESCP, ESMO 2016
55 RCT Optimal timing for surgery after preoperative CRT (6 vs. 12 weeks) 6 weeks 12 weeks Post-operative complications Any 25 (45%) 35 (48%) Wound infection/ 14 (25%) 13 (18%) Delayed healing Anastomotic leak 6 (11%) 1 (1%) Medical (MI, PE etc) 2 (4%) 7 (10%) Other 10 (18%) 20 (27%) Differences in post-operative complications between the two arms were non-significant (p=0.48)
56 Summary of 6 vs. 12 trial 6 weeks 12 weeks Favourable mrtrg mrtdownstaging pcr, pt0 Post-operative complications Clinical benefit
57 Balancing survival with quality of life Short term toxicities Long term complications Permanent sequelae Local recurrence Distant Cure metastases Clinical benefit
58 Acknowledgement National Health Service funding to the National Institute for Health Research Biomedical Research Centre
Carcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
Radiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
RECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Valencia May 2018 State of the art: Standards of care in preoperative treatment for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures:
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
Rectal Cancer : Curative treatment without surgery
Rectal Cancer : Curative treatment without surgery Dieter Hahnloser dieter.hahnloser@chuv.ch CHUV University Hospital Lausanne Switzerland Reasons for intervention (surgery) Cure Live longer Feel better
ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural
Neoadjuvant treatment Evolution and Current Status
Neoadjuvant treatment Evolution and Current Status Dr Andrew See Radiation Oncologist 2017 Rectal Cancer Symposium Friday 10 th November 2017 2 1 Major Randomised Trials Supporting Neoadjuvant CRT Trial
The Role Of The Post-CRT MRI In Assessing Response
Low Rectal Cancer: Is It Safe To Change The Plane Of Surgery? The Role Of The Post-CRT MRI In Assessing Response Nick Battersby, Mit Dattani, Nick West, Graham Branagan, Mark Gudgeon, Phil Quirke, Paris
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
Current Issues and Controversies in the Management of Rectal Cancer
Current Issues and Controversies in the Management of Rectal Cancer Ghazi M. Nsouli MD 11 th Annual Congress of the Lebanese Society of Gastroenterology November 16, 2012 GMN 20121116 1 Staging of rectal
THE BEST OF ESMO 2016
THE BEST OF ESMO 2016 Colorectal cancer Pr Julien TAIEB, Sorbonne Paris Cité and Paris Descartes University Georges Pompidou European Hospital Paris, FRANCE esmo.org DISCLOSURES JT has received research
Management of early rectal cancer: Any role for adjuvant chemotherapy
Management of early rectal cancer: Any role for adjuvant chemotherapy Andrés Cervantes Professor of Medicine CURRENTS CONCEPTS IN RECTAL CANCER DIAGNOSIS AND THERAPY TME surgery Optimal staging by MRI
Opportunity for palliative care Research
Opportunity for palliative care Research Role of Radiotherapy in Multidisciplinary Management of Rectal Cancers Dr Sushmita Pathy Associate Professor Department of Radiation Oncology Dr BRA Institute Rotary
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 State of the art: Radio- /chemotherapy for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
MRI: IMPACT ON RECTAL CANCER CARE AND STANDARDISATION
MRI: IMPACT ON RECTAL CANCER CARE AND STANDARDISATION Professor Gina Brown Consultant Radiologist and Professor of Gastrointestinal Cancer Imaging, The Royal Marsden Hospital and Imperial College, London,
Neues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom
Neues zur neoadjuvanten Vorbehandlung beim Rektumkarzinom Prof. Dr. med. R. Fietkau Strahlenklinik Disclosure I have the following potential confilct(s) of interest to report: Type of affiliation/ financial
Meta analysis in Rectal Cancer
Meta analysis in Rectal Cancer Dr. Monica Irukulla Professor and Head Department of Radiation Oncology Nizam s Institute of Medical Sciences hyderabad Areas of meta analysis in rectal cancers Epidemiology
ADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
Advances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
COLON AND RECTAL CANCER
COLON AND RECTAL CANCER Mark Sun, MD Clinical Associate Professor of Surgery University of Minnesota No disclosures Objectives 1) Understand the epidemiology, management, and prognosis of colon and rectal
L impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
Preoperative adjuvant radiotherapy
Preoperative adjuvant radiotherapy Dr John Hay Radiation Oncology Program BC Cancer Agency Vancouver Cancer Centre The key question for the surgeon Do you think that this tumour can be resected with clear
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
How to deal with patients with isolated peritoneal metastases
ESMO Preceptorship Programme Colorectal Valencia 18-19 May 2018 Michel DUCREUX, MD, PhD Gustave Roussy Cancer Centre, Grand Paris, FRANCE How to deal with patients with isolated peritoneal metastases DISCLOSURE
CREATE Trial Proposal: Survey of current practice and potential trial participation
CREATE Trial Proposal: Survey of current practice and potential trial participation Approximately a quarter of newly diagnosed rectal cancer patients have features on pre-treatment pelvic MRI indicating
COLON AND RECTAL CANCER
No disclosures COLON AND RECTAL CANCER Mark Sun, MD Clinical Assistant Professor of Surgery University of Minnesota Colon and Rectal Cancer Statistics Overall Incidence 2016 134,490 new cases 8.0% of all
COLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
Differential effect of concurrent chemotherapy regimen on clinical outcomes of preoperative chemoradiotherapy for locally advanced rectal cancer
JBUON 2019; 24(2): 470-478 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Differential effect of concurrent chemotherapy regimen on clinical outcomes
Role of MRI for Staging Rectal Cancer
Role of MRI for Staging Rectal Cancer High-resolution MRI has supplanted endoscopic ultrasound for staging rectal cancer. High-resolution MR images closely match histology and can show details such as
Case Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
PATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY
PATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY Jeannelyn S. Estrella, MD Department of Pathology The UT MD Anderson Cancer
Rectal Cancer: Classic Hits
Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
Evidence-Based Series 2-4 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Preoperative or Postoperative Therapy for the Management of Patients with
Long Term Outcomes of Preoperative versus
RESEARCH ARTICLE Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand Pichayada Darunikorn
Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
Radiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
Treatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
Clinical Study Prognostic Value of Mandard and Dworak Tumor Regression Grading in Rectal Cancer: Study of a Single Tertiary Center
ISRN Surgery, Article ID 310542, 8 pages http://dx.doi.org/10.1155/2014/310542 Clinical Study Prognostic Value of Mandard and Dworak Tumor Regression Grading in Rectal Cancer: Study of a Single Tertiary
Adjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain
Adjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain Outline The problem Adjuvant therapy Neoadjuvant therapy Options Conclusion The problem 30 years ago: Local recurrence
M. Kripp, 1 K. Horisberger, 2 S. Mai, 3 P. Kienle, 2 T. Gaiser, 4 S. Post, 2 F. Wenz, 3 K. Merx, 1 and R.-D. Hofheinz 5. 1.
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2015, Article ID 273489, 8 pages http://dx.doi.org/10.1155/2015/273489 Research Article Does the Addition of Cetuximab to Radiochemotherapy
De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
Rectal Cancer. Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco
Rectal Cancer Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco Modern Treatment for Rectal Cancer Improve Local Control Improved
RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY
COLORECTAL CLINICAL SUBGROUP RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY Finalised by: Dr Simon Gollins Mr Andrew Renehan Dr Mark Saunders Mr Nigel Scott Dr Shabbir
SMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
Chemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
Adjuvant treatment for stage III colon cancer
ESMO Preceptorship Programme Rectal cancer Singapur November 2017 Adjuvant treatment for stage III colon cancer Andrés Cervantes Disclosures Consulting and advisory services, speaking or writing engagements,
Rectal Cancer Update 2008 The Last 5 cm. Consensus Building
Rectal Cancer Update 2008 The Last 5 cm Consensus Building Case Distal Rectal Cancer 65 male physician Rectal mass: 5cm from anal verge, 1cm above sphincter? Imaging choice: CT vs MR vs ERUS? Adjuvant
Disclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
Where are we at with organ preservation for rectal cancer? Simon Bach Queen Elizabeth Hospital Birmingham ACPGBI Edinburgh 2016
Where are we at with organ preservation for rectal cancer? Simon Bach Queen Elizabeth Hospital Birmingham ACPGBI Edinburgh 2016 Disclosures Consultant for Johnson and Johnson (Ethicon Inc) Encompasses
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
Background: Patients and methods: Results: Conclusions:
Chapter 7 7 Results of European pooled analysis of IORT containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastase
Cover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38705 holds various files of this Leiden University dissertation. Author: Gijn, Willem van Title: Rectal cancer : developments in multidisciplinary treatment,
Treatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
Case Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological Response
Case Reports in Surgery Volume 2015, Article ID 816491, 5 pages http://dx.doi.org/10.1155/2015/816491 Case Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
Dirk Arnold Lógica de proximidade à população
Doenca Contando metastatica já com 70 anos potencialmente de experiência no resecável: sector da saúde Tratamento igual para colon e para recto? 5 Hospitais Privados CUF 6 Clínicas de ambulatório CUF 6
Neoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant
ESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
2015 EUROPEAN CANCER CONGRESS
2015 EUROPEAN CANCER CONGRESS 25-29 September 2015 Vienna, Austria SUMMARY The European Cancer Congress (ECC 2015) combined the 40th European Society for Medical Oncology (ESMO) congress with the 18th
Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
State-of-the-art of surgery for resectable primary tumors
Early colorectal cancer State-of-the-art of surgery for resectable primary tumors (Special focus on rectal cancer surgery) Stefan Heinrich & Hauke Lang Department of General, Visceral and University Hospital
Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
Rectal cancer management: a team sport The role of radiology and the multidisciplinary conference
Rectal cancer management: a team sport The role of radiology and the multidisciplinary conference W. Donald Buie MD MSc FRCSC Professor of Surgery and Oncology Department of Surgery University of Calgary
Ning Li, Jing Jin, Jing Yu, Shuai Li, Yuan Tang, Hua Ren, Wenyang Liu, Shulian Wang, Yueping Liu, Yongwen Song, Hui Fang, Zihao Yu, Yexiong Li
Original Article Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypi stage after neoadjuvant chemo-radiotherapy versus de novo stage pi cohort: A propensity score-matched
Timing and Deferral of Rectal Surgery Following a Continued Response to Pre-operative Chemoradiotherapy
Timing and Deferral of Rectal Surgery Following a Continued Response to Pre-operative Chemoradiotherapy CCR Reference No.: 2759 Acronym: Deferral of surgery Consultant in Charge Investigators Dr. DM Tait,
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
Introduction. Original Article
Original Article Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX? Vikas Ostwal 1, Reena Engineer
Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
COLORECTAL CARCINOMA
QUICK REFERENCE FOR HEALTHCARE PROVIDERS MANAGEMENT OF COLORECTAL CARCINOMA Ministry of Health Malaysia Malaysian Society of Colorectal Surgeons Malaysian Society of Gastroenterology & Hepatology Malaysian
Anus,Rectum and Colon
JOURNAL OF THE Anus,Rectum and Colon http://journal-arc.jp REVIEW ARTICLE Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer Kazushige Kawai, Soichiro Ishihara, Hiroaki
Disclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study
Original Article Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study Elmer E. van Eeghen 1, Frank den Boer 2, Sandra D. Bakker 1,
Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer
Original Article 1223 Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer Bruce D. Minsky, MD a ; Claus Rödel, MD b ; and Vincenzo Valentini, MD c Abstract The 2 broad approaches
Grandangolo in Radioterapia Oncologica. D. Genovesi; F. Perro/ Is1tuto di Radioterapia Oncologica CHIETI
Grandangolo in Radioterapia Oncologica D. Genovesi; F. Perro/ Is1tuto di Radioterapia Oncologica CHIETI www.radioterapia.unich.it TOPICS ü ESOFAGO & GIUNZIONE ESOFAGO- GASTRICA ü STOMACO ü RETTO ü ANO
Medicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
Systemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
Available at journal homepage:
European Journal of Cancer (2012) 48, 1781 1790 Available at www.sciencedirect.com journal homepage: www.ejconline.com What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin
Role of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
Adjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
Rectal Cancer. GI Practice Guideline
Rectal Cancer GI Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Dr. Francisco Perera MD, FRCPC (Radiation Oncologist) Dr. Jay Engel MD, FRCPC (Surgical Oncologist) Approval Date: 2006 This guideline
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
Case Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
Disclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
CHAPTER 7 Concluding remarks and implications for further research
CONCLUDING REMARKS AND IMPLICATIONS FOR FURTHER RESEARCH CHAPTER 7 Concluding remarks and implications for further research 111 CHAPTER 7 Molecular staging of large sessile rectal tumors In this thesis,
PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
PROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
RECTAL CANCER: Adjuvant Therapy. Maury Rosenstein, MD Montefiore Medical Center December 2012
RECTAL CANCER: Adjuvant Therapy Maury Rosenstein, MD Montefiore Medical Center December 2012 Overview Indications for adjuvant therapy Preoperative Postoperative New Advances Epidemiology Approximately
Latkauskas et al. BMC Cancer (2016) 16:927 DOI /s
Latkauskas et al. BMC Cancer (2016) 16:927 DOI 10.1186/s12885-016-2959-9 RESEARCH ARTICLE reoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer: